Free tool
FAERS Monitor: Qinlock
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213973 or its brand name (Qinlock, Ripretinib). Reports on generic versions are filed under their own applications.
Reports
5,243
Serious
2,276
43% of reports
Hospitalization
1,051
Death reported
497
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue688
- alopecia594
- death381
- underdose374
- extra dose administered357
- nausea338
- drug ineffective334
- hospitalisation319
- disease progression298
- pain295
- constipation292
- diarrhoea279
- inappropriate schedule of product administration278
- product use in unapproved indication267
- neoplasm progression265
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 303 |
| 2021 | 727 |
| 2022 | 833 |
| 2023 | 951 |
| 2024 | 842 |
| 2025 | 1,016 |
| 2026 | 571 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,916 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| extra dose administeredSignal | 357 | 35.7 | 32.2 | 11,910 |
| neoplasm progressionSignal | 265 | 30.8 | 27.4 | 7,567 |
| underdoseSignal | 374 | 20.7 | 18.7 | 6,964 |
| alopeciaSignal | 594 | 12.2 | 11.3 | 6,116 |
| disease progressionSignal | 298 | 10.1 | 9.1 | 2,450 |
| hospitalisationSignal | 319 | 8.3 | 7.5 | 2,065 |
| inappropriate schedule of product administrationSignal | 278 | 6.2 | 5.5 | 1,215 |
| constipationSignal | 292 | 5.4 | 4.8 | 1,045 |
| product use in unapproved indicationSignal | 267 | 4.3 | 3.8 | 687 |
| fatigueSignal | 688 | 3.5 | 3.3 | 1,303 |
| pain | 295 | 1.9 | 1.7 | 134 |
| death | 381 | 1.8 | 1.6 | 133 |
| diarrhoea | 279 | 1.7 | 1.5 | 89 |
| nausea | 338 | 1.7 | 1.5 | 104 |
| drug ineffective | 334 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.